Navigation Links
Biodel Announces Name Change for Lead Product Candidate
Date:9/1/2010

DANBURY, Conn., Sept. 1 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) announced today that Linjeta™ (pronounced lin-JET-uh) will replace VIAject as the proposed trade name for Biodel's  most advanced product candidate.  The change follows FDA's review and acceptance of Linjeta™ as an alternative name for Biodel's more-rapid-acting insulin formulation that is currently under review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Application date of October 30, 2010.  

Dr. Errol De Souza, Biodel 's president and chief executive officer, stated: "Today's news reflects the continued progress of the Linjeta™ new drug application through FDA review and is an important milestone in our effort to commercialize this new drug candidate."

About Biodel Inc. Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes.  Biodel's product candidates are developed using VIAdel™ technology, which reformulates existing FDA-approved peptide drugs.  Biodel's new drug application for Linjeta™, its most advanced product candidate, has been accepted for review by the FDA with a Prescription Drug User Fee Act action date of October 30, 2010.  Earlier-stage product candidates include VIAtab™, a sublingual tablet formulation of insulin, a line of basal insulins and a stabilized formulation of glucagon.  For further information regarding Biodel, please visit the company's website at www.biodel.com. Contact:The Trout Group LLCSeth D. Lewis, +1-646-378-2952
'/>"/>

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ®, provider ... SCM ) and sales and operations planning ( S&OP ) ... Biomanufacturing Summit , which will be held at the ... the conference, join Kinaxis customer Elisabeth Kaszas , Director ...
(Date:1/14/2014)... 14, 2014 During the 1600’s through the ... “The Doctor’s Plague.” In this time period, doctors did not ... at times, to the death of vulnerable patients. In the ... that they may be unwittingly transmitting herpes viruses to their ...
(Date:1/14/2014)... Holloway America today announced an addition ... reports (MTRs) for all pressure vessels and tank parts ... particularly important for equipment that must meet ASME, CE, ... search functionality that allows authorized users to quickly locate ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... Cephalon, Inc. (NASDAQ: CEPH ) today ... Statement with the Securities and Exchange Commission (SEC) urging ... remove Cephalon,s entire Board of Directors and replace them ... of the Statement to shareholders of record together with ...
... NEW YORK, April 21, 2011 Collins Stewart LLC ... healthcare investment banking alliance with Beal Advisors and Liberty ... target, originate and execute public and private equity transactions ... Tree Advisors are US-based boutique healthcare advisory firms. Georgia ...
... 21, 2011 The Stanford University School of ... of a Phase 1/2a clinical trial testing the ... therapy product, SB623, on patients suffering from stable ... regarding this clinical trial, please refer to the ...
Cached Biology Technology:Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 2Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 3Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 4Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 5Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 6Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 7Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 8Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 9Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 10Collins Stewart Announces Formation of Healthcare Investment Banking Alliance 2Collins Stewart Announces Formation of Healthcare Investment Banking Alliance 3Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability 2
(Date:4/20/2014)... crop residue to make ethanol and other biofuels reduces ... gasoline, according to a study published today in the ... by a University of Nebraska-Lincoln team of researchers cast ... meet federal mandates to ramp up ethanol production and ... stalks, leaves and cobs in cornfields after harvest -- ...
(Date:4/18/2014)... adds a twist to the story of how barnyard chickens ... 21 in the journal Proceedings of the National Academy ... chickens that lived 200-2300 years ago in Europe, researchers report ... have looked far different from the chickens we know today. ... associate with modern domestic chickens -- such as their yellowish ...
(Date:4/17/2014)... trials to treat tuberculosis could be the basis for ... bacteria, fungal infections and parasites, yet evade resistance, according ... collaborators. , Led by U. of I. chemistry professor ... drug SQ109 attacks the tuberculosis bacterium, how the drug ... to malaria and how targeting multiple pathways reduces ...
Breaking Biology News(10 mins):Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Ancient DNA offers clues to how barnyard chickens came to be 2Multitarget TB drug could treat other diseases, evade resistance 2
... origins of holiday giving and finds that our early ... arguably the foundational basis of cooperation in humans," writes ... feature of reciprocity is the contingent relationship between acts ... important because it sets the rules for who qualifies ...
... the United States could be grown inexpensively and safely ... of Central Florida molecular biologist has found. , Mice ... Daniell's laboratory through the genetic engineering of tobacco plants ... Institutes of Health researchers. The results of the NIH-funded ...
... -- a critical protein that mediates the body's defense against ... soon have greater therapeutic value as the result of a ... in St. Louis. , "Essentially, we found a way ... Michael J. Holtzman, M.D., the Selma and Herman Seldin Professor ...
Cached Biology News:Effective, safe anthrax vaccine can be grown in tobacco plants 2Effective, safe anthrax vaccine can be grown in tobacco plants 3Greasing interferon's gears may pave way to greater therapeutic benefits, fewer side effects 2
CQCS kit for first KR 4i , (first unit)....
... 384, compatible with hood ... handling system for 384-well ... accurately prepares large quantities ... The Wellpro also performs ...
...
...
Biology Products: